This report was first published by Endpoints News. To see the original version, click here
The new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous studies suggest most of those who start taking GLP-1 drugs quit the medicines within a year.
One startup has a bold solution to the problem. Addition Therapeutics is working on a genetic medicine that would turn a patient’s liver cells into little factories to permanently pump out their own weight loss drugs, the startup told Endpoints News in an exclusive interview.
您已阅读6%（598字），剩余94%（9560字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。